WUXI LIFE (08148) announced its interim results, with profit attributable to shareholders reaching HKD 9.857 million, an increase of 328.75% year-on-year.

01:30 29/08/2026

Wu Xi Life (08148) announced its interim results for the six months ending on June 30, 2026. The group achieved revenue of HKD 56.135 million, an increase of 99.83% year-on-year; the profit attributable to the owners of the company was HKD 9.857 million, an increase of 328.75% year-on-year; earnings per share were HKD 0.0215.

WUXI LIFE (08148) announced its interim results for the six months ended June 30, 2026, reporting revenue of HK$56.135 million, an increase of 99.83% year-on-year; net profit attributable to the company's owners was HK$9.857 million, a year-on-year increase of 328.75%; earnings per share were HK$0.0215.

After Cursor was acquired by SpaceX (SPCX.US), OpenAI announced the termination of cooperation citing Musk's "breach of contract history."

Electra Therapeutics (ETRA.US) has submitted an IPO application for the U.S. stock market, leveraging the current biotech IPO boom to advance the development of new drugs for immune diseases and cancer.

Blue Owl (OWL.US) has teamed up with PIMCO to customize a $2.4 billion GPU financing for IREN (IREN.US).

After Cursor was acquired by SpaceX (SPCX.US), OpenAI announced the termination of cooperation citing Musk's "breach of contract history."

Blue Owl (OWL.US) has teamed up with PIMCO to customize a $2.4 billion GPU financing for IREN (IREN.US).